Bioarctic Ab Class B · OMXSTO:BIOA_B
Bioarctic Ab Class B — Q2 2020 Earnings Presentation
18 slides from Bioarctic Ab Class B's earnings presentation, Jul 10, 2020
Slide 1: Second Quarter Report January-June 2020
BIOARCTIC AB (PUBL) NASDAQ STOCKHOLM: BIOA B Second Quarter Report January-June 2020 Stockholm, July 10, 2020 Gunilla Osswald, PhD, CEO Jan Mattsson, CFO BioArctic AB
Slide 2: Disclaimer
Disclaimer • This presentation has been prepared and produced by BioArctic AB (publ) (“BioArctic”) solely for the benefit of investment analysis of BioArctic and may not be used for any other purpose. Unless otherwise stated, BioArctic is the source for all data contained in this presentation. Such
Slide 3: BioArctic – a unique Swedish biopharma company
BioArctic – a unique Swedish biopharma company Improving life for patients with central nervous system disorders High unmet need for disease-modifying treatments for Alzheimer’s and Parkinson’s diseases creates large commercial opportunity World-class research and development driven organization wit
Slide 4: Q2 2020 highlights
Q2 2020 highlights Operations continue to progress according to plan General • Operations continue to progress according to plan BAN2401 • Recruitment of Alzheimer patients for Clarity AD study ongoing • Swedish clinics now included in Phase 3 study Discovery stage programs • New collaboration initi
Slide 5: Attractive and well-balanced project portfolio combines fully-financed partner projects and cutting-edge proprietary projects
Attractive and well-balanced project portfolio combines fully- financed partner projects and cutting-edge proprietary projects Project Partner Discovery Preclinical Phase 1 Phase 2 Phase 3 ALZHEIMER’S DISEASE BAN2401 Eisai, Biogen1 BAN2401 back-up Eisai AD1801 AD1502 AD1503 AD2603 PARKINSON’S DISEAS
Slide 6: Long-standing and extensive partnerships
Long-standing and extensive partnerships Alzheimer’s disease Parkinson’s disease Partner track record Collaboration and license Partner track record Collaboration and license MEUR 63 MUSD 130 received World’s all-time best-selling received Discovered and developed medicine (BUSD 20) world’s best-sel
Slide 7: BAN2401: potential disease modifying antibody for Alzheimer's disease with positive Phase 2b results now in Phase 3
BAN2401: potential disease modifying antibody for Alzheimer’s disease with positive Phase 2b results now in Phase 3 High unmet medical need BAN2401 unique profile BAN2401 has positive Phase 2b results No existing disease- Unique and targeted binding • Large trial: 856 early Alzheimer’s modifying tre
Slide 8: Broad BAN2401 clinical program – driven by BioArctic's partner Eisai
Broad BAN2401 clinical program – driven by BioArctic’s partner Eisai Disease stage Preclinical AD MCI Mild AD Moderate Severe FDA guideline Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Stage 6 AHEAD 3-45 Phase 3 Program – Clarity AD Phase 3 confirmatory planned study – ongoing • Eisai and ACTC planning t
Slide 9: ABBV-0805: potential disease modifying antibody for Parkinson's disease
ABBV-0805: potential disease modifying antibody for Parkinson’s disease with strong preclinical results now in Phase 1 High unmet medical need Unique profile Preclinical proof of concept No existing disease- Unique and targeted binding Reduction of neurotoxic alpha-synuclein modifying treatment prof
Slide 10: Continued progress in collaboration with AbbVie on alpha-synuclein
Continued progress in collaboration with AbbVie on alpha-synuclein Collaboration highlights ABBV-0805 advancing in clinical trials • ABBV-0805 targeting disease modification in December January February March Parkinson’s disease 2018 2019 2019 2019 2020 • Potential to expand to earlier stage Parkins
Slide 11: Early stage portfolio continues to develop well
Early stage portfolio continues to develop well Alzheimer’s disease Parkinson’s disease Other CNS disorders Blood-brain barrier Diagnostics technology Discovery stage Discovery stage Neurodegeneration Blood-brain barrier Diagnostics programs projects research technology platform • Continued • 4 full
Slide 12: Finance Summary
Finance Summary 12 BioArctic AB
Slide 13: Net revenues and operating profit Q2 2020
Net revenues and operating profit Q2 2020 Net Revenues (MSEK) OPEX by item (MSEK) Operating Profit/Loss (MSEK) 515 100 430 86 80 61 60 53 44 48 40 43 36 40 127 171 94 20 33 63 17 -11 -21 -38 4 21 26 36 7 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2018 2019 2020 2018 20
Slide 14: Cash related and net profit Q2 2020
Cash related and net profit Q2 2020 Cash Balance (MSEK) Cash Flow From Operating Net Result (MSEK) 1 256 Activities (MSEK) 335 1 218 1 170 334 1 113 1 077 1 009 1 050 917 97 -31 -49 -54 -36 -20 100 -89 26 14 -8 -17 4 -38 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2018 20
Slide 15: Upcoming news and closing remarks
Upcoming news and closing remarks 15 BioArctic AB
Slide 16: Upcoming news flow
Upcoming news flow Alzheimer’s disease Parkinson’s disease Other CNS disorders Blood-brain barrier Diagnostis technology BAN2401 (Eisai) ABBV-0805 (AbbVie) Neurodegeneration Blood-brain barrier Diagnostics • To present data at • Complete Phase 1 research technology platform • Continue international
Slide 17: BioArctic: With Patients in Mind
BioArctic: With Patients in Mind Built on science Projects in focus Value-driven leadership Great science Great projects Great people 17 BioArctic AB
Slide 18: Contact and next report
GUNILLA OSSWALD, CEO JAN MATTSSON, CFO NEXT REPORT & IR CONTACT • Next Report: Interim report Jan-Sep 2020 on October 14, 2020 • Contact: Oskar Bosson, VP Communications & IR +46 704 10 71 80 ir@bioarctic.se To subscribe to financial reports/press releases and for more information, please visit www.